Each year, an estimated 1.2 million cancer patients undergo cytotoxic chemotherapy in the United States; and approximately 800,000 (67%) will become anemic. ESPs, a type of hematopoietic agent, stimulate the bone marrow to increase the production of red blood cells and have been shown to result in a clinically significant improvement of anemia associated with chemotherapy. Total global revenue for recombinant ESP drugs was slightly approximately six billion USD in 2016. Recombinant ESP drugs are one of the first class of protein drugs to feel the effects of biosimilars. Slightly less than half of the branded drugs in this class are biosimilars. This report examines each recombinant ESPs in detail and forecasts the effects of the uptake of biosimilars on the global recombinant ESP market.
Report Brochure (Download PDF)
Report Order Form (Download PDF)
Recombinant Erythropoietin Stimulating Proteins – What You Will Learn
• What are the recombinant ESP products that are have been given marketing authorization by the FDA or the EMA?
• Who supplies the API; the finished product? Who is the labeler; the marketer? What is the host system?
• Who are the major recombinant ESP suppliers; what are their facilities, and where are they located?
• What are the as-supplied characteristics for each ESP product and how are they administered?
• What is the probable impact of biosimilars on approved ESP products in North America; in Europe?
• What does the market look like today? What is the forecast for how it will look in 2022?
• What will be the impact of economic, technology, and regulatory factors on the commercial potential of recombinant ESPs?
Recombinant Erythropoietin Stimulating Proteins – Summary of Contents
Recombinant ESPs – The Market Opportunity
Therapeutic Demand Drivers
Sourcing Recombinant ESPs
Collaborations & Relationships
Recombinant ESPs – Indications & Markets
Anemia due to CKD
Pre-donation of Autologous Blood
Recombinant ESPs– Product Analysis
Epoetin Alfa Hexal
Recombinant ESPs – Market Data & Forecasts
Packaging and Administration
Managed Care Initiatives